In situ kinetic modelling of intestinal efflux in rats: Functional characterization of segmental differences and correlatlon with in vitro results

Biopharmaceutics and Drug Disposition

Volumn 28, Issue 5, 2007, Pages 229-239

  González Alvarez, Isabel ^a   Fernández Teruel, Carlos ^b   Casabó Alós, Vicente G ^a   Garrigues, Teresa M ^a   Polli, James E ^c   Ruiz García, Ana ^d   Bermejo, Marival ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b Intervalence Biokinetics SL   (Spain)

^c UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^d AMGEN INC   (United States)

Author keywords

Absorption kinetic modelling; P glycoprotein; Rat intestinal permeability; Transporter levels

Indexed keywords

4 AMINOHIPPURIC ACID; CNV 97100; CYCLOSPORIN A; GLYCOPROTEIN P; QUINIDINE; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL CULTURE; COLON; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ABSORPTION; DUODENUM; EXPERIMENTAL MODEL; FUNCTIONAL ANATOMY; ILEUM; IN VITRO STUDY; INTESTINE ABSORPTION; INTESTINE MOTILITY; INTESTINE MUCOSA PERMEABILITY; INTESTINE PERFUSION; JEJUNUM; KINETICS; MALE; MATHEMATICAL MODEL; NONHUMAN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; REFERENCE VALUE; TISSUE DISTRIBUTION; WISTAR RAT;

ALGORITHMS; ANIMALS; CIPROFLOXACIN; COLON; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOROQUINOLONES; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL ABSORPTION; INTESTINE, SMALL; INTESTINES; KINETICS; MALE; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; MUSCARINIC ANTAGONISTS; P-AMINOHIPPURIC ACID; P-GLYCOPROTEIN; PERMEABILITY; QUINIDINE; RATS; RATS, WISTAR; VASODILATOR AGENTS; VERAPAMIL;

EID: 34547494525     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.548     Document Type: Article

References (17)

1. Shen LL, Mitscher LA, Sharma PN, et al. Mechanism of inhibition of DNA gyrase by quinolone antibacterials: a cooperative drug-DNA binding model. Biochemistry 1989; 28: 3886-3894.
2. Sanchez-Castano G, Ruiz-Garcia A, Banon N, et al. Intrinsic absolute bioavailability prediction in rats based on in situ absorption rate constants and/or partition coefficients: 6-fluoroquinolones. J Pharm Sci 2000; 89: 1395-1403.
3. Doluisio JT, Billups NF, Dittert LW, Sugita ET, Swintosky JV. Drug absorption. I. An in situ rat gut technique yielding realistic absorption rates. J Pharm Sci 1969; 58: 1196-1200.
4. Park GB, Mitra AK. Mechanism and site dependency of intestinal mucosal transport and metabolism of thymidine analogues. Pharm Res 1992; 9: 326-331.
5. Suttle AB, Brouwer KL. Regional gastrointestinal absorption of ranitidine in the rat. Pharm Res 1995; 12: 1311-1315.
6. Brouwers JR. Drug interactions with quinolone antibacterials. Drug Saf 1992; 7: 268-281.
7. Yumoto R, Murakami T, Nakamoto Y, Hasegawa R, Nagai J, Takano M. Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds. J Pharmacol Exp Ther 1999; 289: 149-155.
8. Ruiz-Garcia A, Lin H, Pla-Delfina JM, Hu M. Kinetic characterization of secretory transport of a new ciprofloxacin derivative (CNV97100) across Caco-2 cell monolayers. J Pharm Sci 2002; 91: 2511-2519.
9. Takara K, Ohnishi N, Horibe S, Yokoyama T. Expression profiles of drug-metabolizing enzyme CYP3A and drug efflux transporter multidrug resistance 1 subfamily mRNAS in small intestine. Drug Metab Dispos 2003; 31: 1235-1239.
10. Stephens RH, O'Neill CA, Warhurst A, Carlson GL, Rowland M, Warhurst G. Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia. J Pharmacol Exp Ther 2001; 296: 584-591.
11. Valenzuela B, Nacher A, Ruiz-Carretero P, Martin-Villodre A, Lopez-Carballo G, Barettino D. Profile of P-glycoprotein distribution in the rat and its possible Influence on the salbutamol intestinal absorption process. J Pharm Sci 2004; 93: 1641-1648.
12. Rodriguez-Ibanez M, Nalda-Molina R, Montalar-Montero M, Bermejo M, Merino V, Garrigues TM. Transintestinal secretion of ciprofloxacin, grepafloxacin and sparfloxacin: in vitro and in situ inhibition studies. Eur J Pharm Biopharm 2003; 55: 241-246.
13. Seelig A, Landwojtowicz E. Structure-activity relationship of P-glycoprotein substrates and modifiers. Eur J Pharm Sci 2000; 12: 31-40.
14. Guo A, Marinaro W, Hu P, Sinko PJ. Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos 2002; 30: 457-463.
15. Luo FR, Paranjpe PV, Guo A, Rubin E, Sinko P. Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1. Drug Metab Dispos 2002; 30: 763-770.
16. Williams GC, Liu A, Knipp G, Sinko PJ. Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2). Antimicrob Agents Chemother 2002; 46: 3456-3462.
17. Stewart BH, Chan OH, Lu RH, et al. Comparison of intestinal permeabilities determined in multiple in vitro and in situ models: relationship to absorption in humans. Pharm Res 1995; 12: 693-699.